Sensus Healthcare (SRTS) AI Stock Analysis

• Market Cap: $77.62M
• Dividend Yield: N/A
• Average Volume (3M): 63.69K
• Price to Earnings (P/E): 42.9
• Beta (1Y): 1.08
• Revenue Growth: 24.75%
• EPS Growth: -61.29%
• Country: US
• Employees: 54
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Devices
• EPS (TTM): -0.16
• Shares Outstanding: 16,445,036
• 10 Day Avg. Volume: 89,100
• 30 Day Avg. Volume: 63,687
• PEG Ratio: -0.53
• Price to Book (P/B): 1.32
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 15.18
• Enterprise Value/Market Cap: 0.65
• Enterprise Value/Revenue: 0.32
• Enterprise Value/Gross Profit: 2.29
• Enterprise Value/Ebitda: 1.53
• 1Y Price Target: $11.25
• Price Target Upside: 99.12% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 68 Neutral
• Price Target: $5.00 ▼(-11.50%Downside)

Sensus Healthcare's overall stock score is driven by strong financial performance in terms of revenue and balance sheet health, despite challenges in cash flow. Technical indicators show mixed momentum, and the high P/E ratio suggests overvaluation. The earnings call highlights potential for future growth, although immediate challenges persist.

Positive Factors

Clinical Efficacy

Positive results from a study highlight the efficacy of combining surgical excision of keloids with adjuvant Superficial Radiation Therapy (SRT) using Sensus' SRT-100, showing no keloid recurrence.

Sales Growth

Sensus anticipates surpassing 900 capital sales with expectations to reach 1,000, suggesting strong sales growth.

Trade Show Interest

Sensus Healthcare received heightened interest at key industry trade shows, acting as a catalyst for growth.

Negative Factors

Competition

SkinCure announced it would be exhibiting a fourth-generation SRT device that would compete with Sensus SRT-100 Vision image-guided SRT offering.

Revenue Decline

Total revenue was $8.3M, representing a 22% YoY decline and missing the projection of $8.7M, with a net loss of $2.6M.

Valuation Concerns

Some investors perceive Sensus and SkinCure as competitors due to similarities in their business models, potentially affecting Sensus' current valuation.

Sensus Healthcare Business Overview & Revenue Model

Company Description

Sensus Healthcare (SRTS) is a medical device company specializing in non-invasive treatment solutions for non-melanoma skin cancers and other dermatological conditions. The company operates in the healthcare sector, focusing on developing and providing innovative, cost-effective, and patient-friendly technologies. Its flagship product, the SRT-100, utilizes Superficial Radiation Therapy (SRT) to treat skin cancer and keloids without the need for surgery, offering a painless alternative with minimal side effects.

How the Company Makes Money

Sensus Healthcare generates revenue primarily through the sale and leasing of its SRT-100 devices to dermatology clinics, hospitals, and healthcare facilities. The company also earns income from service contracts and maintenance agreements, providing ongoing support and ensuring optimal performance of their devices. Additionally, Sensus may engage in partnerships or collaborations with other healthcare providers to expand its market reach and drive sales growth. Revenue is further supplemented by training and support services offered to healthcare professionals using their technology.

Sensus Healthcare Financial Statement Overview

Summary

Sensus Healthcare demonstrates strong revenue and profit growth with a solid balance sheet characterized by low leverage and high equity. However, challenges remain with negative free cash flow, suggesting a need for improved cash management.

Income Statement

Sensus Healthcare showed remarkable revenue growth of 71.3% from the previous year. The gross profit margin improved significantly to 58.4%, reflecting increased operational efficiency. Net profit margin also improved substantially to 15.9%, indicating enhanced profitability. However, the EBIT margin of 19.3% and EBITDA margin of 19.3% suggest room for improvement in controlling operating expenses.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 89.8%, demonstrating financial stability. The debt-to-equity ratio is low at 0.01, indicating minimal leverage and reduced financial risk. Return on equity improved significantly to 11.9%, showcasing effective utilization of shareholder funds. Overall, the balance sheet reflects solid financial health.

Cash Flow

Sensus Healthcare's free cash flow improved but remains negative, indicating potential challenges in cash management. The operating cash flow to net income ratio is negative, suggesting a need to enhance cash generation from operations. Despite these challenges, the free cash flow deficit has narrowed, showing some progress towards achieving positive cash flows.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	41.81M	24.41M	44.53M	27.04M	9.58M
Gross Profit	24.43M	14.06M	29.63M	16.99M	5.25M
EBITDA	8.52M	79.00K	14.83M	4.73M	-6.10M
Net Income	6.65M	485.00K	24.24M	4.12M	-4.72M
Balance Sheet
Total Assets	62.16M	53.71M	56.73M	32.24M	28.01M
Cash, Cash Equivalents and Short-Term Investments	22.06M	23.15M	25.52M	14.52M	14.91M
Total Debt	602.00K	783.00K	1.02M	225.00K	1.38M
Total Liabilities	6.34M	4.87M	8.67M	6.22M	6.51M
Stockholders Equity	55.83M	48.84M	48.07M	26.02M	21.50M
Cash Flow
Free Cash Flow	-1.11M	-2.37M	-1.57M	-414.00K	-792.73K
Operating Cash Flow	-831.00K	-2.15M	-1.41M	-286.00K	-434.18K
Investing Cash Flow	-276.00K	-187.00K	14.84M	129.00K	7.03M
Financing Cash Flow	15.00K	-40.00K	-2.43M	-231.00K	210.01K

Sensus Healthcare Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.65
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRTS, the sentiment is Positive. The current price of 5.65 is above the 20-day moving average (MA) of 4.60, above the 50-day MA of 4.72, and below the 200-day MA of 5.84, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 71.62 is Negative, neither overbought nor oversold. The STOCH value of 86.99 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SRTS.

Sensus Healthcare Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SRTS	68 Neutral	$77.62M	42.95	3.46%	―	24.75%	-61.29%
HYPR	53 Neutral	$87.18M	―	-67.86%	―	0.34%	6.20%
NSPR	53 Neutral	$74.75M	―	-113.95%	―	8.49%	6.09%
Sector *	52 Neutral	$7.62B	0.05	-63.03%	2.44%	16.33%	0.31%
ICCM	46 Neutral	$67.66M	―	-173.47%	―	0.34%	9.38%
CTSO	44 Neutral	$63.86M	―	-94.65%	―	-5.86%	50.76%
RBOT	39 Underperform	$71.72M	―	-104.36%	―	―	-1455.58%

Sensus Healthcare Corporate Events

Sensus Healthcare Elects New Director at Annual Meeting

At the Annual Meeting of Stockholders held on May 27, 2025, Sensus Healthcare elected Anthony Petrelli as a Class I director for a three-year term. Stockholders approved an amendment to the 2017 Incentive Plan, extending its term and increasing the share issuance limit. Additionally, the compensation of the company’s executive officers for 2024 was approved on an advisory basis, and Berkowitz Pollack Brant Advisors + CPAs, LLP was ratified as the independent registered public accountant for the fiscal year ending December 31, 2025.

The most recent analyst rating on (SRTS) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Sensus Healthcare stock, see the SRTS Stock Forecast page.